Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + mitoxantrone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Parenteral
01
Overview
A combination chemotherapy regimen consisting of methotrexate and mitoxantrone. This combination is primarily used in the treatment of advanced breast cancer. Mitoxantrone is a synthetic anthracenedione that intercalates into DNA, causes crosslinks and strand breaks, and inhibits topoisomerase II. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, disrupting DNA synthesis and cellular replication. The combination leverages complementary mechanisms to achieve therapeutic effects against cancer cells.
02
Targets
DNADHFR (Dihydrofolate reductase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on methotrexate + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + mitoxantrone.